Availability, health-care costs, and utilization patterns of biologics in Taiwan

Value in Health

Volumn 15, Issue 1 SUPPL., 2012, Pages

  Hsieh, Chee Ruey ^a   Liu, Ya Ming ^b  

^a INSTITUTE OF ECONOMICS   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

access to new biologics; biologics; health care costs; technology diffusion

Indexed keywords

A 10AB 04; A 10AB 05; A 10AC 04; A 10AD 04; A 10AD 05; A 10AE 04; A 16AB 02; ADALIMUMAB; B 03XA 02; BETA1A INTERFERON; BEVACIZUMAB; CETUXIMAB; ETANERCEPT; IMIGLUCERASE; INFLIXIMAB; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INTERFERON BETA SERINE; J 06BB 16; L 01XC 02; L 01XC 03; L 01XC 06; L 01XC 07; L 03AA 02; L 03AA 13; L 03AB 07; L 03AB 08; L 04AB 01; L 04AB 02; L 04AB 04; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PALIVIZUMAB; PEGINTERFERON ALPHA2A; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; COMORBIDITY; CONFERENCE PAPER; COST UTILITY ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUBLIC HOSPITAL; RHEUMATOID ARTHRITIS; TAIWAN;

AGED; BIOLOGICAL AGENTS; COSTS AND COST ANALYSIS; DRUG UTILIZATION; FEES, PHARMACEUTICAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TAIWAN;

EID: 84862951284     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.025     Document Type: Conference Paper

References (14)

1. A. Baumann Early development of therapeutic biologicspharmacokinetics Curr Drug Metab 7 2006 15 21
2. E. Lacan, S. Amur, P. Mummanneni The emerging role of pharmacogenomics in biologics Clin Pharmacol Ther 82 2007 466 471 (Pubitemid 47414357)
3. M. Trusheim, M.L. Aitken, E.R. Berndt Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? 13 1 2010 Article 4 http://www.bepress.com/fhep/13/1/4 [Accessed November 30, 2011]
4. T.J. Giezen, A.K. Mantel-Teeuwisse, S.M.J.M. Straus Safety-related regulatory actions for biologicals approved in the United States and the European Union JAMA 300 2008 1887 1896
5. F. Simon Market access for biopharmaceuticals: new challenges Health Aff (Millwood) 25 2006 1363 1369
6. C.R. Hsieh Pharmaceutical policy in Taiwan K. Eggleston, Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific 2009 Brookings Institution Press Baltimore, MD
7. P.M. Danzon, Y.R. Wang, L. Wang The impact of price regulation on the launch delay of new drugs: evidence from 25 markets in the 1990s Health Econ 14 2005 269 292 (Pubitemid 40360763)
8. P.M. Danzon, M.F. Furukawa Prices and availability of biopharmaceuticals: an international comparison Health Aff (Millwood) 25 2006 1353 1362 (Pubitemid 44497636)
9. L.J. Kay, I.D. Griffiths UK consultant rheumatologists' access to biological agents and views on the BSR biologics register Rheumatology 45 2006 1376 1379 (Pubitemid 44605472)
10. C.R. Hsieh, C.W. Kuo Cost of chronic hepatitis B virus infection in Taiwan J Clin Gastroenterol 38 Suppl. 2004 S148 S152
11. Y.M. Liu, C.H. Hsieh New drugs and the growth of health expenditures: empirical evidence from diabetic patients in Taiwan Health Econ 2011 10.1002/hec.1724
12. Y.M. Liu, Y.H. Kao Yang, C.R. Hsieh The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan Soc Sci Med 72 2011 919 927
13. M.E. Charlson, P. Pompei, K.L. Ales, C.R. Mackenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
14. S.D. Sullivan, D.L. Veenstra, P.J. Chen Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan J Gastroenterol Hepatol 22 2007 1494 1499 (Pubitemid 47274568)